Table 3.

Results of the question on awareness and need for standardization of desensitization for hypersensitivity reactions in gynecological cancer.

Question	Not Involved in Chemotherapy Treatment n = 30 (%)	Involved in Chemotherapy Treatment n = 103 (%)
Aware of the possibility of desensitization of patients with HSRs to platinum/taxane prior to this survey
Yes	12 (40.0)	57 (55.3)
No	16 (53.3)	7 (6.8)
Other	0 (0)	2 (1.9)
No answer	2 (2.7)	37 (35.9)
A need to standardize the management of platinum and taxane HSRs in gynecological cancer and to develop international guidelines?
Yes	25 (83.3)	61 (59.2)
No	2 (6.7)	4 (3.9)
No answer	3 (10.0)	38 (36.9)

HSR = Hypersensitivity reaction.